Logo image of CHRS

COHERUS ONCOLOGY INC (CHRS) Stock Price, Quote, News and Overview

NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD

0.7617  -0.03 (-3.63%)

After market: 0.7501 -0.01 (-1.52%)

CHRS Quote, Performance and Key Statistics

COHERUS ONCOLOGY INC

NASDAQ:CHRS (6/13/2025, 8:00:00 PM)

After market: 0.7501 -0.01 (-1.52%)

0.7617

-0.03 (-3.63%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.43
52 Week Low0.66
Market Cap88.30M
Shares115.93M
Float105.32M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO11-06 2014-11-06


CHRS short term performance overview.The bars show the price performance of CHRS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

CHRS long term performance overview.The bars show the price performance of CHRS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CHRS is 0.7617 USD. In the past month the price decreased by -0.82%. In the past year, price decreased by -54.93%.

COHERUS ONCOLOGY INC / CHRS Daily stock chart

CHRS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.61 337.52B
AMGN AMGEN INC 14.22 158.74B
GILD GILEAD SCIENCES INC 14.21 136.81B
VRTX VERTEX PHARMACEUTICALS INC N/A 116.96B
REGN REGENERON PHARMACEUTICALS 11.94 57.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.16B
ARGX ARGENX SE - ADR 100.5 35.29B
ONC BEONE MEDICINES LTD-ADR 6.9 29.17B
BNTX BIONTECH SE-ADR N/A 25.62B
NTRA NATERA INC N/A 22.58B
BIIB BIOGEN INC 8.26 19.14B
INSM INSMED INC N/A 17.98B

About CHRS

Company Profile

CHRS logo image Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 228 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. Its commercial product, LOQTORZI (toripalimab-tpzi), is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in three ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a cytolytic anti-CCR8 antibody which is in Phase I study in patients with advanced solid tumors. CHS-1000 is a humanized Fc-modified IgG1 monoclonal antibody targeting ILT4.

Company Info

COHERUS ONCOLOGY INC

C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200

Redwood City CALIFORNIA 94065 US

CEO: Dennis M. Lanfear

Employees: 228

CHRS Company Website

CHRS Investor Relations

Phone: 16506493530

COHERUS ONCOLOGY INC / CHRS FAQ

What is the stock price of COHERUS ONCOLOGY INC today?

The current stock price of CHRS is 0.7617 USD. The price decreased by -3.63% in the last trading session.


What is the ticker symbol for COHERUS ONCOLOGY INC stock?

The exchange symbol of COHERUS ONCOLOGY INC is CHRS and it is listed on the Nasdaq exchange.


On which exchange is CHRS stock listed?

CHRS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for COHERUS ONCOLOGY INC stock?

13 analysts have analysed CHRS and the average price target is 4.78 USD. This implies a price increase of 527.15% is expected in the next year compared to the current price of 0.7617. Check the COHERUS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is COHERUS ONCOLOGY INC worth?

COHERUS ONCOLOGY INC (CHRS) has a market capitalization of 88.30M USD. This makes CHRS a Micro Cap stock.


How many employees does COHERUS ONCOLOGY INC have?

COHERUS ONCOLOGY INC (CHRS) currently has 228 employees.


What are the support and resistance levels for COHERUS ONCOLOGY INC (CHRS) stock?

COHERUS ONCOLOGY INC (CHRS) has a support level at 0.76 and a resistance level at 0.76. Check the full technical report for a detailed analysis of CHRS support and resistance levels.


Is COHERUS ONCOLOGY INC (CHRS) expected to grow?

The Revenue of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -80.67% in the next year. Check the estimates tab for more information on the CHRS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy COHERUS ONCOLOGY INC (CHRS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does COHERUS ONCOLOGY INC (CHRS) stock pay dividends?

CHRS does not pay a dividend.


When does COHERUS ONCOLOGY INC (CHRS) report earnings?

COHERUS ONCOLOGY INC (CHRS) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of COHERUS ONCOLOGY INC (CHRS)?

COHERUS ONCOLOGY INC (CHRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).


What is the Short Interest ratio of COHERUS ONCOLOGY INC (CHRS) stock?

The outstanding short interest for COHERUS ONCOLOGY INC (CHRS) is 31.44% of its float. Check the ownership tab for more information on the CHRS short interest.


CHRS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CHRS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CHRS. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CHRS Financial Highlights

Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 50.94% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -35.29%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-9.37%
Sales Q2Q%-90.14%
EPS 1Y (TTM)50.94%
Revenue 1Y (TTM)-34.58%

CHRS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to CHRS. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -38.38% and a revenue growth -80.67% for CHRS


Ownership
Inst Owners51.83%
Ins Owners6.33%
Short Float %31.44%
Short Ratio19.39
Analysts
Analysts78.46
Price Target4.78 (527.54%)
EPS Next Y-38.38%
Revenue Next Year-80.67%